The COVID-19 outbreak is anticipated to have a negative impact on the growth of the chronic hepatitis B market as there is the implementation of lockdown in many countries. The COVID-19 pandemic affected the supply chain and decreased blood donations all over the world. The entire healthcare industry has focused on life-saving and COVID-19-related drug classes during the pandemic. Thus, COVID-19 has a significant negative impact on the chronic hepatitis B market. However, the government initiatives to provide safer healthcare facilities and a rise in blood donation rate for the treatment of COVID-19 with blood plasma is anticipated to grow in post-pandemic situations.